cell therapy getting some coverage over the weekend ...
and what do we read into this release ..... ???? hope it doesn't slow down the decision to elect ....
Prima partner and Cancer Vaccine leader Biomira announces new CEO and Chairman 1 September 2006, Melbourne, Australia: Prima BioMed Limited (ASX:PRR) notes an announcement by its commercialisation partner for its CVacTM cancer cell therapy, Biomira Inc (Nasdaq: BIOM) appointing a new CEO and Chairman of the Board. Prima makes the following observations: • Dr Robert Kirkman, MD, and Dr Christopher Henney, PhD, are highly respected for their expertise and experience in cancer vaccine development; • Biomira has committed to building a leading cancer therapeutics company • Biomira has committed to a strategy of growth through acquisition or in-licensing of additional cancer therapies Biomira Inc has an exclusive option for commercialisation rights in the North American and European markets for Prima’s CVacTM cell therapy. Prima’s Australian phase IIa clinical trial in ovarian cancer is expected to be completed by the end of the year.
PRR Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)